Literature DB >> 12750168

Mechanisms for T-cell selective cytotoxicity of arabinosylguanine.

Carlos O Rodriguez1, Christine M Stellrecht, Varsha Gandhi.   

Abstract

Nelarabine, prodrug of arabinosylguanine (ara-G), has demonstrated T-lymphoblastic antileukemic activity in cell lines and in the clinic. To investigate the mechanism for lineage-specific toxicity, the effects of ara-G were compared in CEM (T-lymphoblast), Raji (B-lymphoblast), and ML-1 (myeloid) cell lines. CEM cells were the most sensitive to ara-G-induced apoptosis and accumulated the highest levels of ara-G triphosphate (ara-GTP). However, compared with myeloid and B-lineage cell lines, CEM cells incorporated fewer ara-G molecules-which were at internucleotide positions in all 3 cell lines- into DNA. Ara-G induced an S-phase arrest in both Raji and ML-1, while in CEM the S-phase cells decreased with a concomitant increase in the sub-G1 population. Within 3 hours of ara-G treatment, the levels of soluble Fas ligand (sFasL) in the medium increased significantly in CEM cultures. In parallel, an induction of FasL gene expression was observed by real-time reverse transcriptase-polymerase chain reaction (RT-PCR). Pretreatment of CEM cells with a Fas antagonistic antibody inhibited ara-G-mediated cell death. These results demonstrate that high ara-GTP accumulation in T cells results in an S phase-dependent apoptosis induced by ara-G incorporation into DNA, which may lead to a T cell-specific signal for the induction and liberation of sFasL. Subsequently, the sFasL induces an apoptotic response in neighboring non-S-phase cells. In contrast, myeloid and B cells accumulated lower levels of ara-GTP and arrested in S phase, blocking any apoptotic signaling.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12750168     DOI: 10.1182/blood-2003-01-0317

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

1.  The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience.

Authors:  P Jain; H Kantarjian; F Ravandi; D Thomas; S O'Brien; T Kadia; J Burger; G Borthakur; N Daver; E Jabbour; M Konopleva; J Cortes; N Pemmaraju; M A Kelly; M Cardenas-Turanzas; R Garris; S Faderl
Journal:  Leukemia       Date:  2013-10-25       Impact factor: 11.528

Review 2.  How were new medicines discovered?

Authors:  David C Swinney; Jason Anthony
Journal:  Nat Rev Drug Discov       Date:  2011-06-24       Impact factor: 84.694

3.  Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Authors:  Kimberly P Dunsmore; Meenakshi Devidas; Stephen B Linda; Michael J Borowitz; Naomi Winick; Stephen P Hunger; William L Carroll; Bruce M Camitta
Journal:  J Clin Oncol       Date:  2012-06-25       Impact factor: 44.544

4.  The discovery of medicines for rare diseases.

Authors:  David C Swinney; Shuangluo Xia
Journal:  Future Med Chem       Date:  2014-06       Impact factor: 3.808

5.  Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434.

Authors:  Stuart S Winter; Kimberly P Dunsmore; Meenakshi Devidas; Nancy Eisenberg; Barbara L Asselin; Brent L Wood; Marcia S Leonard Rn; John Murphy; Julie M Gastier-Foster; Andrew J Carroll; Nyla A Heerema; Mignon L Loh; Elizabeth A Raetz; Naomi J Winick; William L Carroll; Stephen P Hunger
Journal:  Pediatr Blood Cancer       Date:  2015-03-08       Impact factor: 3.167

6.  Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia.

Authors:  Kelly M Reilly; David F Kisor
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

7.  Nelarabine in the treatment of refractory T-cell malignancies.

Authors:  Andrew M Roecker; Amy Stockert; David F Kisor
Journal:  Clin Med Insights Oncol       Date:  2010-12-01

8.  Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Authors:  Stuart S Winter; Zeyu Jiang; Hadya M Khawaja; Timothy Griffin; Meenakshi Devidas; Barbara L Asselin; Richard S Larson
Journal:  Blood       Date:  2007-05-10       Impact factor: 22.113

9.  Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia.

Authors:  Kumudha Balakrishnan; Farhad Ravandi; Shanta Bantia; Anna Franklin; Varsha Gandhi
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-06-15

Review 10.  Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer.

Authors:  William B Parker
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.